Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 OGN | Healthcare | $13.90 | 4.00M | $3.65B | 17.58 | 0.58% | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OGN | Organon | 13.90 | 6.44 | 86.38% |
| Name | Price | % Change | |
|---|---|---|---|
| OGN | $13.90 | +86.38% |
Organon (OGN) will present results from a post hoc sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating the efficacy of VTAMA cream
Organon (OGN) announced the poster presentation of new real-world evidence at the American College of Rheumatology, ACR, Annual Meeting, held November 6-11, 2026 in Orlando, Florida. The poster evaluates the
Organon & Co. ($OGN) announced an update on their ongoing clinical study. Study Overview: Organon & Co. (OGN) has updated its Phase 3 study, officially titled “A Phase 3 Study
Organon (OGN) announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis, AD, will be presented at the 2026 American
Organon ( ($OGN) ) has provided an update. On October 30, 2026, Organon & Co. filed its Form 10-Q and furnished supplemental non-GAAP financial metrics for the quarter and nine
Organon (OGN) announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine device, through 6 years of use at
Organon (OGN) announced the US Food and Drug Administration, FDA, has accepted for review Sebela Women’s Health’s supplemental New Drug Application, sNDA, for Miudella for an extended duration of use
Organon (OGN) announced the Miudella Risk Evaluation and Mitigation Strategy, REMS, Program is now open for enrollment on its website. The website enables healthcare providers, healthcare settings, and eligible specialty
Organon & Co. (OGN) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street analysts expect Organon & Co. to post earnings of $0.91 per share.
Organon ( ($OGN) ) has shared an update. On July 31, 2026, Organon & Co. filed its Form 10-Q with the SEC, releasing financial results for the quarter ended June
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| OGN | Feb 18, 2027TBA | $3.65B | ― | ― | -0.13 | 17.58 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
